The Role of Neoadjuvant Chemotherapy in NSCLC

摘要: Neoadjuvant chemotherapy to reduce tumor size before surgery or radiologic treatment is now a feasible option in the of non-small cell lung cancer (NSCLC). Patients clinical stage IIIA N2 disease who were previously poor prognostic subset when treated with are being neoadjuvant chemotherapy, followed by radiotherapy, an attempt improve survival rates. Published trials report response rates 50 80% and median 18–27 months. Two small have reported striking benefits over alone. Other larger ongoing should answer some questions raised these two trials.